


Metformin therapeutic as post-ischemic conditioning agent

June 29 2017



(HealthDay)—Metformin has therapeutic potential as a post-ischemic



conditioning agent, according to a study published online June 23 in *Cardiovascular Therapeutics*.

Rajesh Ramachandran, Ph.D., and Mini Saraswathy, Ph.D., from the University of Kerala in Thiruvananthapuram, India, examined the role of metformin in preventing apoptotic events preceding ischemic reperfusion injury and its effect on apoptotic markers.

The researchers found that postconditioning with metformin at a concentration of 2.5 µg/mL effectively maintained cell viability and membrane stability of H9C2 cardiomyoblast <u>cells</u> after ischemic injury. The authors established a decrease in apoptosis cell death via fluorescent staining and Annexin V/FITC flow cytometric analysis. The DNA fragmentation and comet length were significantly reduced in metformintreated ischemic cells (P = 0.0001). After ischemic injuries, there was an increase in protein carbonyl content and a decrease in nitrate levels, which were alleviated by treatment with metformin. Metformin treatment also enhanced wound closure. Apoptotic proteins such as FASL and anti-apoptotic proteins such as BcL2, BcL, XL, and p21 were synchronized by metformin.

"The results envisage therapeutic potential of <u>metformin</u> as a postischemic conditioning agent," the authors write.

More information: <u>Abstract</u> Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Metformin therapeutic as post-ischemic conditioning agent (2017, June 29) retrieved 25 January 2023 from <u>https://medicalxpress.com/news/2017-06-metformin-therapeutic-post-ischemic-conditioning-agent.html</u>



This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.